MARKET

FBIO

FBIO

Fortress Biotech Inc
NASDAQ
3.949
+0.289
+7.90%
Opening 12:05 01/02 EST
OPEN
3.780
PREV CLOSE
3.660
HIGH
4.069
LOW
3.730
VOLUME
1.21M
TURNOVER
--
52 WEEK HIGH
4.200
52 WEEK LOW
1.325
MARKET CAP
122.57M
P/E (TTM)
-13.4778
1D
5D
1M
3M
1Y
5Y
1D
Mustang Bio Director Neil Herskowitz Reports Disposal of Common Shares
Reuters · 12/30/2025 21:18
Mustang Bio Director David Jin Reports Acquisition of Common Shares
Reuters · 12/30/2025 21:15
Weekly Report: what happened at FBIO last week (1222-1226)?
Weekly Report · 12/29/2025 10:05
Mustang Bio Inc. held annual shareholder meeting
Reuters · 12/23/2025 21:06
Weekly Report: what happened at FBIO last week (1215-1219)?
Weekly Report · 12/22/2025 10:05
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO
NASDAQ · 12/20/2025 05:44
Fortress Biotech Amends Credit Agreement with Oaktree
TipRanks · 12/15/2025 22:45
Fortress Biotech Announces Unregistered Sale of Warrants in Private Placement
Reuters · 12/15/2025 21:33
More
About FBIO
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.

Webull offers Fortress Biotech Inc stock information, including NASDAQ: FBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FBIO stock methods without spending real money on the virtual paper trading platform.